Dr. Mark Liu, M.D.
Pulmonology (Pulmonary Disease Physician)
5501 Hopkins Bayview Cir
Baltimore, MD 21224
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (1975)
- Years since graduation
- 51
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 207
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1975Medical school: University of Maryland School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MD license D21394 -
Clinical & Laboratory Immunology (Internal Medicine) Physician
MD license D21394
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Johns Hopkins Bayview Medical Center Baltimore, MD
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 207
- Services billed
- 484
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 77 | 39 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 77 | 62 |
| Established patient office or other outpatient visit, 40-54 minutes | 70 | 48 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 62 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 35 |
| Critical care, first 30-74 minutes | 18 | 11 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Baltimore, MD | 38 |
| Azithromycin Other prescribers in Baltimore, MD | 18 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Baltimore, MD | 16 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Baltimore, MD | 16 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Baltimore, MD | 15 |
| Pantoprazole Sodium Other prescribers in Baltimore, MD | 15 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Baltimore, MD | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $23.98 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $23.98 |
|---|
| Food and Beverage | $23.98 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $207,715 in research payments for these studies, mostly to the institutions running them.
- Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
Sanofi US Services Inc. · Terminated · NCT06033833 - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chron…
AstraZeneca Pharmaceuticals LP - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT05421598 - A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic O…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.